Search - tctmd.com

Displaying 61 - 80 of 225

Sort: Relevancy | Date

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

Diabetes Progression in Statin-Treated Patients: VA Data

News Daily News

Diabetes Progression in Statin-Treated Patients: VA Data

Michael O'Riordan

October 06, 2021

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

October 05, 2021

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

News Daily News

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

Michael O'Riordan

October 04, 2021

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

News Daily News

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

Michael O'Riordan

October 01, 2021

Vasopressor/Steroid Combo Jump-starts Circulation for In-Hospital Cardiac Arrests

News Daily News

Vasopressor/Steroid Combo Jump-starts Circulation for In-Hospital Cardiac Arrests

September 30, 2021

Cardiogenic Shock Teams May Lower Mortality in Cardiac ICUs

News Daily News

Cardiogenic Shock Teams May Lower Mortality in Cardiac ICUs

September 21, 2021

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

News Daily News

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

Michael O'Riordan

September 20, 2021

Title (ideally under 60 characters) DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

September 15, 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

News Conference News HFSA 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Michael O'Riordan

September 14, 2021

Long-term Anticoagulation After Unprovoked VTE: New Insights

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

September 13, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

News Daily News

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

September 09, 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.